Posted by Michael Wonder on 14 Aug 2016
Use of intermediate endpoints in the economic evaluation of new treatments for advanced cancer and methods adopted when suitable overall survival data are not available
15 August 2016 - This study assessed the use of intermediate endpoints in the economic evaluation of new treatments for advanced cancer and the methodological approaches adopted when overall survival (OS) data are unavailable or of limited use.
Intermediate endpoints are widely used in the economic evaluation of new treatments for advanced cancer in order to estimate OS. Currently, different methods are used in the absence of suitable OS data and the choice of an appropriate method depends on many factors including the data availability.
